NSN Subsidiary Neurosona Wins Excellence Award for Presenting Clinical Results on Depression Treatment at the 19th Pacific Rim College of Psychiatrists Conference (PRCP)

Neurosona, a specialized company in brain disease treatment platforms, announced that Professor Seok Jeong-ho of the Department of Psychiatry at Gangnam Severance Hospital, Yonsei University College of Medicine, who is the clinical research director for depression at Neurosona, presented interim analysis results of a clinical study on depression at the 19th Pacific Rim College of Psychiatrists (PRCP 2021) conference and received the Best Presentation Award.

The presentation was titled “Effect of Low-intensity Focused Ultrasound Stimulation in Patients with Major Depressive Disorder: Interim analysis of an exploratory clinical trial,” and covered the interim analysis of an exploratory clinical trial evaluating the effects of Neurosona’s Low-Intensity Focused Ultrasound (LIFU) device stimulation on patients with major depressive disorder.

In this presentation, Professor Seok Jeong-ho showed that stimulating the brain region known to have impaired function in depression patients (the left dorsolateral prefrontal cortex) with Neurosona’s LIFU device resulted in significant improvement compared to a group receiving sham stimulation.

The Pacific Rim College of Psychiatrists (PRCP) is the largest regional psychiatric society integrating Asia, Oceania, and North America, and the 19th PRCP conference was held in Seoul from April 8 to 10.

Neurosona CEO Seon-il Seo stated, “This presentation and award served as an opportunity to reaffirm the great interest and expectations in the academic community regarding brain disease treatment research using Neurosona’s LIFU device.” He added, “We are also very much looking forward to the upcoming pivotal clinical trial for major depressive disorder.”

CEO Seo further explained, “Currently, Neurosona has completed procedures for subjects in exploratory clinical trials for depression and Alzheimer’s as of last March and is preparing to report the completion of clinical trials to the Ministry of Food and Drug Safety. We have also recently completed the selection of a contract research organization (CRO) with the goal of conducting pivotal clinical trials for depression and Alzheimer’s within the third quarter of this year.”

Neurosona is a specialized company focused on LIFU-based brain disease treatment platforms, which are expected to be effective not only for depression but also for Alzheimer’s, pain, consciousness disorders, sleep disorders, stroke, and other brain diseases. The company is actively conducting clinical research on these brain diseases in collaboration with leading hospitals in Korea.

Meanwhile, the interim analysis results of Neurosona’s exploratory clinical trial on patients with major depressive disorder will also be presented at the Korean Society of Ultrasound in Medicine conference scheduled for May 13.